

### 關於此計劃

#### About the Sponsorship

為了令更多癌症患者能受惠於 Onco-PDO™ 體外藥物測試，InvitroCue 將繼續為符合條件的志願者提供免費或半資助測試服務，並會提供 Onco-PDO™ 報告讓主診醫生獲得患者個體化藥物反應的參考數據。

In order to benefit more cancer patients, InvitroCue continues to provide full sponsorship or 50% sponsorship for cancer patients who meet our "Sponsorship Criteria" below for Onco-PDO™ test.

此計劃有助 InvitroCue 研究擴展 Onco-PDO™ 服務標準及支援藥物研發，令社會更多癌症患者可受惠於 Onco-PDO™ 服務及改善癌症患者抗癌生活質素，有賴您的支持及參與。

This programme will also help us to extend our research and development to standardize our Onco-PDO™ service and support cancer drug development. We hope more cancer patients could benefit from the test and their quality of life could be significantly improved accordingly. Thank you for your support and participation!



### Onco-PDO™ 體外癌症藥物反應測試 Test

Onco-PDO™ 癌症藥物測試已通過CE歐盟認證，此測試使用癌症患者的自身腫瘤樣本，在體外複製多個「迷你腫瘤」（腫瘤類器官）進行試藥，主診醫生可以為患者揀選多達8種NCCN指引內的指定藥物，減少患者須承受多次試藥的副作用。

主診醫生可根據Onco-PDO™ 報告，評估患者體外試藥後的數據，揀選最適合患者病情的抗癌藥物，節省治療期的一分一秒，讓患者儘早獲得更理想的治療效果、提升病情控制及抗癌生活質素。

The Onco-PDO™ test has passed CE EU certification. This test uses the cancer patient's own tumor samples to replicate multiple "mini tumors" (tumor organoids) in vitro for drug testing. The attending doctor can select up to 8 designated drugs within the NCCN guidelines for testing. The test will minimize the unnecessary treatment and/or side effects that patients may undergo multiple trials of drugs.

According to the Onco-PDO™ test report, the attending doctor can make a comprehensive consideration of patient's medical condition and in vitro drug response information to select the most suitable drugs for the patient. This will save every minute and second of the treatment period, so that the patient may obtain a better therapeutic effect sooner with improved disease control and quality of life against cancer.

### 資助條件

#### Sponsorship Criteria

#### 1. 免費測試（價值港幣 36,000）

100% Sponsorship (value at HK\$36,000)

- 適用於所有診斷患有鼻咽癌、胰腺癌、肝癌及子宮頸癌的患者。

For patients from public and private hospitals who have diagnosed with Nasopharyngeal carcinoma, Pancreatic, Liver and Cervical cancer.

#### 2. 半資助測試（價值港幣 18,000）

50% Sponsorship (value at HK\$18,000)

- 公立醫院患者被診斷患有除上述四種癌症以外的癌症類型，例如但不限於肺癌、乳腺癌、結直腸癌、胃癌、膀胱癌、前列腺癌、腦癌、腎癌、卵巢癌和小童神經母細胞瘤。

For patients from public hospitals who have diagnosed with other cancer type such as but not limited to Lung, Breast, Colorectal, Gastric, Bladder, Prostate, Brain, Kidney, Ovarian cancer, and Paediatric Neuroblastoma.

### 贊助公司

#### Sponsored by



#### 使命及願景 Mission and Vision

透過評估各種最新研發的藥物，我們將具有意義的科研臨床數據帶給醫藥界，旨在開發更佳、更快速見效及更經濟實惠的癌症治療方案，努力實現——

為患者提供更好的治療，建立更健康的城市。

By enabling assessments of the best ways for drugs to be developed, we impart to the industry valuable knowledge in creating better, faster, and more affordable disease treatments, working towards the company's goal of creating a healthier society by providing patients with the best possible care.

WhatsApp 查詢



+852 6281 0072

招募計劃於 2023 年 07 月 01 日開展，為期 1 年。詳情如下：

The recruitment will start from 01 July 2023 for a period of one year. Details are as follows:

#### 🔍 適用患者 Applicable Patients:

- 對象 Subjects: I-IV 期癌症患者 Any stage of cancer patients (Stage I – IV)
- 年齡 Age: 18-70 歲 18-70 years old
- 性別 Gender: 男女均可 Both Male and Female
- 樣本要求 Specimen requirements: 活性腫瘤樣本 Viable tumor specimens
- 電郵登記 Email registration: [contact.hk@invitrocue.com](mailto:contact.hk@invitrocue.com)
- WhatsApp 查詢 Enquiry: 6281 0072 (<https://bit.ly/3salPAe>)

\*\*\*特別須知：為免患者須承擔額外進行手術的風險，Invitrocue 會將已預約於 2 個月內進行腫瘤活組織切除手術的患者優先納入考慮

\*\*\*Important notice: To avoid patients bearing the risk of additional surgery, Invitrocue will give priority to patients who have made an appointment for tumor biopsy or surgery in two months' time.

#### 📌 報名方法 For Registration:

有興趣人士可經 WhatsApp 或以上電郵進行登記，Invitrocue 團隊會在收到志願者登記後聯絡登記人仕進行簡單諮詢，登記人仕須同意進行約 10 分鐘電話訪問。

Interested patients can register via WhatsApp or the above email. The Invitrocue team will contact you for a brief consultation after receiving your registration. You must agree to have a telephone interview for about 10 minutes.

#### 🔍 計劃流程 The Workflow:

- 1 志願者登記參加資助計劃後，Invitrocue 團隊會先與患者會談約 10 分鐘以了解患者基本診斷資料；  
After registration, the Invitrocue team will first talk with the patient on the phone for about 10 minutes to understand the patient's basic diagnostic information;
- 2 Invitrocue 團隊約見主診醫生進一步了解患者醫療診斷詳情及向醫生解釋腫瘤樣本採集須知；  
Invitrocue team will make appointment to see the attending doctor to understand more about the patient's medical diagnosis details and explain to the doctor the instructions for tumor sample collection;
- 3 Invitrocue 約見患者及主診醫生簽署知情同意書，並與主診醫生確認為患者揀選的 8 種 NCCN 腫瘤臨床實踐指南列明之適用癌症藥物，正式參與此計劃；  
Invitrocue team will meet the patient and the attending doctor to sign the Informed Consent Form and Requisition Form for Onco-PDO™ test, and confirm with the attending doctor for the selection of 8 applicable cancer drugs for testing from the NCCN Clinical Practice Guidelines in Oncology for the patient;
- 4 手術當日，Invitrocue 團隊會即日收集腫瘤樣本並運送至位於香港科學園之實驗室進行處理；  
On the date of surgery, Invitrocue team will collect the tumor specimens on the same day and transport them to the laboratory in Hong Kong Science and Technology Parks for tissue processing;
- 5 腫瘤細胞活性如成功通過測試，將繼續進行 Onco-PDO™ 體外癌症藥物反應測試；  
If the tumor cell viability is successfully passed, the Onco-PDO™ test will be proceeded;
- 6 2-3 週後 Invitrocue 團隊會將 Onco-PDO™ 報告結果寄送主診醫生。  
Within 2 – 3 weeks' time, Invitrocue team will send the Onco-PDO™ report to the attending doctor.

Invitrocue 會將收集之個人資料保密並以匿名方式進行研究，確保緊守個人私隱條例。

Invitrocue will keep all collected personal information confidential. Any relevant research will be conducted anonymously, and we ensure strict compliance with personal privacy regulations.

如有任何爭議，Invitrocue (Hong Kong) Limited 將保留最終決定權。

In case of any dispute, Invitrocue (Hong Kong) Limited reserves the right of final decision.

#### Invitrocue (Hong Kong) Limited

- ☎ +852 2838 6998
- ☎ +852 6281 0072
- 📍 Unit 612, Biotech Center 2, 11W Science Park West Avenue, Shatin, N.T., HK
- 🌐 [www.invitrocue.com](http://www.invitrocue.com)

